Reacción a "AI designs functional bacteriophages from scratch"

The work by King et al. is one of the first examples of the potential of what is beginning to be termed generative genomics: the computational de novo design of microbial genomes — and, predictably, in the future, of eukaryotic genomes as well — to endow them with specific functions. As has been the case at other points in the history of biology, the first demonstrations of this type of advance are carried out in relatively simple systems, in this case bacteria and bacteriophages.

In my view, the study’s most significant scientific contribution is not merely the technical success achieved, but the demonstration of a much deeper principle: natural evolution has explored only a small fraction of the potential functional space. Consequently, it is possible to conceive and construct chromosomes and biological systems with architectures, compositions and functional properties that differ substantially from those we know in nature. This idea extraordinarily broadens the horizons of synthetic biology and redefines our conception of what constitutes a possible genome.

The article describes the rapid development of bacteriophages capable of eliminating pathogens against which the conventional antibiotic arsenal is no longer effective. Against a backdrop of growing antimicrobial resistance, this possibility represents a contribution of enormous biomedical value. However, the same technology also highlights the dilemma posed by disruptive innovations. The ability to design viruses targeted against pathogenic bacteria implies, by the same logic, the possibility of generating viruses targeted against beneficial microorganisms or essential components of the microbiome. Furthermore, if these strategies were to be extended to viruses with tropism for eukaryotic cells, opportunities such as the design of highly specific oncolytic viruses would arise, but so too would worrying scenarios, such as the creation of viruses with selective affinity for certain cell types, tissues or even population groups.

These possibilities do not call into question the enormous scientific value of the work, but they do raise legitimate questions about biosafety, governance and the regulatory framework that should accompany the development of generative genomics. As has repeatedly been the case in the history of science, the same technology can serve to solve problems or, in the absence of adequate precautions, become a source of new risks. The challenge lies not only in expanding our technological capabilities, but also in developing the regulatory and social mechanisms that will enable us to harness its benefits whilst minimising potential misuse.